Literature DB >> 19942924

Hematology: first-line bortezomib benefits patients with multiple myeloma.

Meletios A Dimopoulos1, Evangelos Terpos.   

Abstract

Bortezomib-based regimens are beneficial in the treatment of patients with symptomatic, newly diagnosed and relapsed or refractory multiple myeloma. researchers who investigated the efficacy and safety of single-agent bortezomib as first-line therapy in patients with myeloma have particularly emphasized the incidence and management of peripheral neuropathy, which is the most common adverse effect of bortezomib administration.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19942924     DOI： 10.1038/nrclinonc.2009.171

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

Review 1.  Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Authors:  J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

2.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Authors:  Mauricio Pineda-Roman; Maurizio Zangari; Jeff Haessler; Elias Anaissie; Guido Tricot; Frits van Rhee; John Crowley; John D Shaughnessy; Bart Barlogie
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

3.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Authors:  Jean-Luc Harousseau; Michel Attal; Xavier Leleu; Jacques Troncy; Brigitte Pegourie; Anne-Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Jean-Gabriel Fuzibet; Marc Renaud; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

4.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

5.  Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

Authors:  Cyrille Hulin; Thierry Facon; Philippe Rodon; Brigitte Pegourie; Lotfi Benboubker; Chantal Doyen; Mamoun Dib; Gaelle Guillerm; Bruno Salles; Jean-Paul Eschard; Pascal Lenain; Philippe Casassus; Isabelle Azaïs; Olivier Decaux; Laurent Garderet; Claire Mathiot; Jean Fontan; Ingrid Lafon; Jean Marc Virion; Philippe Moreau
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 6.  Bortezomib in multiple myeloma.

Authors:  Evangelos Terpos; Maria Roussou; Meletios-Athanassios Dimopoulos
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-05       Impact factor: 4.481

7.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

8.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authors:  Paul G Richardson; Wanling Xie; Constantine Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David E Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh Kesari; Hannah R Briemberg; Robert L Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie-Lee Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544
  8 in total
  3 in total

1.  CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.

Authors:  Yu Yang Ng; Zhicheng Du; Xi Zhang; Wee Joo Chng; Shu Wang
Journal:  Cancer Gene Ther       Date:  2021-09-01       Impact factor: 5.987

Review 2.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

3.  The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.

Authors:  Lara J Bou Malhab; Simon Descamps; Benedicte Delaval; Dimitris P Xirodimas
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.